Abstract
In Australia, rates of obesity in the general population are on the rise. The growing incidence of obesity and higher rates of metabolic syndrome in mental health patients places this group of people at a much higher risk for type 2 diabetes and cardiovascular disease. Treatment effects via psychotropic medications, and lifestyle factors such as diet and exercise suggests that attention needs to be drawn to this vulnerable population. Assessment and the ongoing monitoring of physical health is essential in the prevention of major physical illness in people with a mental disorder.
Keywords: Mental illness, obesity, type 2 diabetes, cardiovascular disease, psychotropic medications
Related eBooks
Related Articles
-
Ivabradine: The Hope for a Good Treatment of Ischemic Heart Disease
Current Medicinal Chemistry Molecular Pharmacology of Non-L-type Calcium Channels
Current Pharmaceutical Design The Clinical Problems of Hypertension Treatment in Hemodialysis Patients
Current Vascular Pharmacology The Renin Angiotensin System in the Regulation of Angiogenesis
Current Pharmaceutical Design Patent Selections:
Recent Patents on Cardiovascular Drug Discovery (Discontinued) Role of Contrast-Enhanced Ultrasound in the Follow-up of Endo-Vascular Aortic Aneurysm Repair: an Effective and Safe Surveillance Method
Current Pharmaceutical Design Impact of Percutaneous Closure of Interatrial Shunts on Migraine Attacks: Single-Operator Series and Review of the Literature
Reviews on Recent Clinical Trials Do Adult Stem Cells Ameliorate the Damaged Myocardium? Human Cord Blood as a Potential Source of Stem Cells
Current Vascular Pharmacology Therapeutic Potential of High Mobility Group Box-1 in Ischemic Injury and Tissue Regeneration
Current Vascular Pharmacology Recent Patents in Cardiac Resynchronization Therapy
Recent Patents on Biomedical Engineering (Discontinued) The Effect of Antihypertensive Agents on Insulin Sensitivity, Lipids and Haemostasis
Current Vascular Pharmacology Vascular Protection to Increase the Safety of Tissue Plasminogen Activator for Stroke
Current Pharmaceutical Design Modulators of Vascular Sex Hormone Receptors and their Effects in Estrogen-Deficiency States Associated with Menopause
Recent Patents on Cardiovascular Drug Discovery (Discontinued) Antiplatelet Therapies: Platelet GPIIb / IIIa Antagonists and Beyond
Current Pharmaceutical Design Viral Heart Disease and Acute Coronary Syndromes - Often or Rare Coexistence?
Current Pharmaceutical Design Prevention of Ischemic Stroke: Surgery
Current Drug Targets Current Status of Renal Artery Angioplasty and Stenting for Resistant Hypertension: A Case Series and Review of the Literature
Current Hypertension Reviews Indicators of Cardiovascular Risk in Metabolic Syndrome: Long Term Follow-up in Italian Patients
Current Vascular Pharmacology Berberine Encapsulated PLGA-PEG Nanoparticles Modulate PCSK-9 in HepG2 Cells
Cardiovascular & Hematological Disorders-Drug Targets Survey of Mortality Due to Influenza A in North of Iran, 2015-2016
Current Respiratory Medicine Reviews